ClinicalTrials.gg

Vitiligo clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 343 studies for Vitiligo across more than 10 countries. 96 are recruiting or about to start. 312 of them are mainly about Vitiligo (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
132
Status unknown
65
Recruiting
48
Not yet recruiting
43
Active, not recruiting
24
Terminated
19

Phase

Phase 2
87
Phase 3
41
Phase 4
24
Phase 1
23
Early Phase 1
8

Where

United States
80
Egypt
48
France
45
China
39
Canada
29
Italy
16

Who develops what

Add Vitiligo to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 22 programs from 22 companies, 22 with this as their studies’ main aim; 7 with a live phase 3 study; 12 primary completions in the next 12 months. Compare AbbVie, argenx and Chongqing Genrix Biopharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ruxolitinibApproved: US 2011 · EU 2012☆ Track2 live phase-3 studies: NCT06804811, NCT06548360Incyte Corporation
FXS5626☆ Track1 live phase-3 study: NCT07840820Fosun Pharma
MH004☆ Track1 live phase-3 study: NCT07682506Minghui Pharmaceutical
upadacitinibApproved: US 2019 · EU 2019☆ Track2 live phase-3 studies: NCT07896434, NCT06118411AbbVie
povorcitinib phosphate☆ Track1 live phase-3 study: NCT07865312Dermavon Holdings Limited

The 5 in phase 3 with the nearest primary completion, of 22 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.EI-001 · Elixiron Immunotherapeutics (Hong Kong) Ltd. · Phase 2 main aimNCT07223229 Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients — primary endpoint: Percent change in F-VASI from baseline · 45 enrolled
  • 31 Dec 2026 est.QY201 · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 2 main aimNCT07712523 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo — primary endpoint: Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24 of treatment. · 200 enrolled
  • 14 Feb 2027 est.MT-II · Hudson Biotech · Phase 2 main aimNCT07437560 Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo — primary endpoint: Change from baseline in Vitiligo Area Scoring Index (VASI) total score · 60 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Vitiligo studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 5 open · Tyrosine kinase inhibitors (TKIs) 5 open · Corticosteroids 1 open · Antimetabolites 5

Coming up

43studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger. 18 (38%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 8 (17%) take healthy volunteers.

Recruiting studies that take each age, of 48
AgeWomenMen
1012 (25%)12 (25%)
1843 (90%)43 (90%)
3043 (90%)43 (90%)
4043 (90%)43 (90%)
5041 (85%)41 (85%)
6538 (79%)37 (77%)
7526 (54%)25 (52%)
8518 (38%)17 (35%)

Across all 343 studies, recruiting or not: 44% stop at 75 or younger and 30% at 65; 30% take children; <1% are for women only and 1% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Vitiligo studies take

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 219 mo16–26 · 44 studies——
Phase 331 mo25–44 · 18 studies——
Interventional, no phase17 mo8–32 · 67 studies—19 mo8–33 · 63 studies
Observational21 mo10–… · 25 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 343. Browse all 343 → or search them.